Trial Profile
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Oct 2023
Price :
$35
*
At a glance
- Drugs Tominersen (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms GEN-EXTEND
- Sponsors Roche
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 14 May 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 30-Mar-2022), according to European Clinical Trials Database record.
- 04 May 2022 Planned End Date changed from 25 Mar 2022 to 25 Mar 2023.